Publication | Closed Access

Immunogenicity and tolerability of an investigational formulation of interferon-β1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis

Clinical Immunology48-Week Interim AnalysesAutoimmune DiseaseMedicineImmunodeficienciesImmune RegulationImmunologyClinical TrialsHumoral ImmunityImmunologic DiseaseImmune FunctionMultiple SclerosisImmunotherapyNeuroimmunologyPhase Iiib Study